{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:34:51Z","timestamp":1790670891714,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peripheral T cell lymphomas (PTCL) is a heterogenous group of non-Hodgkin lymphoma and many patients remain refractory to the frontline therapy. Identifying new prognostic markers and treatment is an unmet need in PTCL. We analyzed phospho-STAT3 (pSTAT3) expression in a cohort of 169 PTCL tumors and show overall 38% positivity with varied distribution among PTCL subtypes with 27% (16\/59) in PTCL-NOS; 29% (11\/38) in AITL, 57% (13\/28) in ALK-negative ALCL, and 93% in ALK-pos ALCL (14\/15), respectively. Correlative analysis indicated an adverse correlation between pSTAT3 and overall survival (OS). PTPN6, a tyrosine phosphatase and potential negative regulator of STAT3 activity, was suppressed in 62% of PTCL-NOS, 42% of AITL, 60% ALK-neg ALCL, and 86% of ALK-pos ALCL. Loss of PTPN6 combined with pSTAT3 positivity predicted an infwere considered significantferior OS in PTCL cases. In vitro treatment of TCL lines with azacytidine (aza), a DNA methyltransferase inhibitor (DNMTi), restored PTPN6 expression and decreased pSTAT3. Combining DNMTi with JAK3 inhibitor resulted in synergistic antitumor activity in SUDHL1 cell line. Overall, our results suggest that PTPN6 and activated STAT3 can be developed as prognostic markers, and the combination of DNMTi and JAK3 inhibitors as a novel treatment for patients with PTCL subtypes.<\/jats:p>","DOI":"10.1038\/s41408-018-0138-8","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T10:52:14Z","timestamp":1542019934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma"],"prefix":"10.1038","volume":"8","author":[{"given":"Jing Jing","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"O\u2019byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary J.","family":"Stenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0526","authenticated-orcid":false,"given":"Matthew J.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda E.","family":"Wellik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-4808","authenticated-orcid":false,"given":"Andrew L.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen D.","family":"McPhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"key":"138_CR1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose, J., Armitage, J. & Weisenburger, D.International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol. 26, 4124\u20134130 (2008).","journal-title":"J. Clin. Oncol."},{"key":"138_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1053\/j.seminhematol.2013.11.003","volume":"51","author":"P Gaulard","year":"2014","unstructured":"Gaulard, P. & de Leval, L. Pathology of peripheral T-cell lymphomas: where do we stand? Semin. Hematol. 51, 5\u201316 (2014).","journal-title":"Semin. Hematol."},{"key":"138_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.34","volume":"4","author":"R Briski","year":"2014","unstructured":"Briski, R. et al. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood Cancer J. 4, e214 (2014).","journal-title":"Blood Cancer J."},{"key":"138_CR4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ctrv.2014.08.001","volume":"40","author":"B Coiffier","year":"2014","unstructured":"Coiffier, B. et al. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. Cancer Treat. Rev. 40, 1080\u20131088 (2014).","journal-title":"Cancer Treat. Rev."},{"key":"138_CR5","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798\u2013809 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"138_CR6","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.1182\/blood-2012-05-428466","volume":"120","author":"M Gupta","year":"2012","unstructured":"Gupta, M. et al. Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab\/R-CHOP. Blood 120, 4400\u20134406 (2012).","journal-title":"Blood"},{"key":"138_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.immuni.2012.03.016","volume":"36","author":"JL Casanova","year":"2012","unstructured":"Casanova, J. L., Holland, S. M. & Notarangelo, L. D. Inborn errors of human JAKs and STATs. Immunity 36, 515\u2013528 (2012).","journal-title":"Immunity"},{"key":"138_CR8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","volume":"36","author":"GR Stark","year":"2012","unstructured":"Stark, G. R. & Darnell, J. E. Jr. The JAK-STAT pathway at twenty. Immunity 36, 503\u2013514 (2012).","journal-title":"Immunity"},{"key":"138_CR9","doi-asserted-by":"publisher","unstructured":"Manso R., et al. Mutations in the JAK\/STAT pathway genes and activation of the pathway, a relevant finding in nodal peripheral T-cell lymphoma. Br. J. Haematol. (2017). https:\/\/doi.org\/10.1111\/bjh.14984.","DOI":"10.1111\/bjh.14984"},{"key":"138_CR10","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ng.3358","volume":"47","author":"L Jiang","year":"2015","unstructured":"Jiang, L. et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma. Nat. Genet. 47, 1061\u20131066 (2015).","journal-title":"Nat. Genet."},{"key":"138_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/leu.2015.202","volume":"30","author":"AM Roncero","year":"2016","unstructured":"Roncero, A. M. et al. Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development. Leukemia 30, 94\u2013103 (2016).","journal-title":"Leukemia"},{"key":"138_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1158\/2159-8290.CD-12-0028","volume":"2","author":"GC Koo","year":"2012","unstructured":"Koo, G. C. et al. Janus kinase 3-activating mutations identified in natural killer\/T-cell lymphoma. Cancer Discov. 2, 591\u2013597 (2012).","journal-title":"Cancer Discov."},{"key":"138_CR13","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/ng.587","volume":"42","author":"M Kleppe","year":"2010","unstructured":"Kleppe, M. et al. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat. Genet. 42, 530\u2013535 (2010).","journal-title":"Nat. Genet."},{"key":"138_CR14","doi-asserted-by":"publisher","first-page":"47771","DOI":"10.1074\/jbc.C100583200","volume":"276","author":"MP Myers","year":"2001","unstructured":"Myers, M. P. et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J. Biol. Chem. 276, 47771\u201347774 (2001).","journal-title":"J. Biol. Chem."},{"key":"138_CR15","doi-asserted-by":"publisher","first-page":"39718","DOI":"10.1074\/jbc.M005615200","volume":"275","author":"N Aoki","year":"2000","unstructured":"Aoki, N. & Matsuda, T. A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b. J. Biol. Chem. 275, 39718\u201339726 (2000).","journal-title":"J. Biol. Chem."},{"key":"138_CR16","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1182\/blood-2008-09-179762","volume":"113","author":"M Gupta","year":"2009","unstructured":"Gupta, M. et al. A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation. Blood 113, 5206\u20135216 (2009).","journal-title":"Blood"},{"key":"138_CR17","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1182\/blood-2009-05-220889","volume":"114","author":"M Gupta","year":"2009","unstructured":"Gupta, M. et al. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 114, 2926\u20132935 (2009).","journal-title":"Blood"},{"key":"138_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27\u201355 (1984).","journal-title":"Adv. Enzyme Regul."},{"key":"138_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/annonc\/mdv486","volume":"27","author":"M Gupta","year":"2016","unstructured":"Gupta, M. et al. Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Ralpha as predictors of event-free survival in T-cell lymphoma. Ann. Oncol. 27, 165\u2013172 (2016).","journal-title":"Ann. Oncol."},{"key":"138_CR20","doi-asserted-by":"crossref","first-page":"44703","DOI":"10.18632\/oncotarget.6300","volume":"6","author":"C Demosthenous","year":"2015","unstructured":"Demosthenous, C., Han, J. J., Hu, G., Stenson, M. & Gupta, M. Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma. Oncotarget 6, 44703\u201344713 (2015).","journal-title":"Oncotarget"},{"key":"138_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/leu.2013.251","volume":"28","author":"TE Witzig","year":"2014","unstructured":"Witzig, T. E. et al. Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: implications for epigenetic therapy. Leukemia 28, 147\u2013154 (2014).","journal-title":"Leukemia"},{"key":"138_CR22","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1007\/s13277-013-1590-5","volume":"35","author":"L Sooman","year":"2014","unstructured":"Sooman, L. et al. PTPN6 expression is epigenetically regulated and influences survival and response to chemotherapy in high-grade gliomas. Tumour Biol. 35, 4479\u20134488 (2014).","journal-title":"Tumour Biol."},{"key":"138_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3892\/or.2015.4347","volume":"35","author":"W Wang","year":"2016","unstructured":"Wang, W. et al. Promoter hypermethylation of PTPL1, PTPN6, DAPK, p16 and 5-azacitidine inhibits growth in DLBCL. Oncol. Rep. 35, 139\u2013146 (2016).","journal-title":"Oncol. Rep."},{"key":"138_CR24","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","volume":"98","author":"JF Bromberg","year":"1999","unstructured":"Bromberg, J. F. et al. Stat3 as an oncogene. Cell 98, 295\u2013303 (1999).","journal-title":"Cell"},{"key":"138_CR25","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1182\/blood-2007-04-087734","volume":"111","author":"BB Ding","year":"2008","unstructured":"Ding, B. B. et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111, 1515\u20131523 (2008).","journal-title":"Blood"},{"key":"138_CR26","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/sj.leu.2404323","volume":"20","author":"Y Han","year":"2006","unstructured":"Han, Y. et al. Restoration of shp1 expression by 5-AZA-2\u2019-deoxycytidine is associated with downregulation of JAK3\/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. Leukemia 20, 1602\u20131609 (2006).","journal-title":"Leukemia"},{"key":"138_CR27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.celrep.2016.09.018","volume":"17","author":"MR Hassler","year":"2016","unstructured":"Hassler, M. R. et al. Insights into the pathogenesis of anaplastic large-cell lymphoma through genome-wide DNA methylation profiling. Cell Rep. 17, 596\u2013608 (2016).","journal-title":"Cell Rep."},{"key":"138_CR28","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nchembio815","volume":"2","author":"D Herman","year":"2006","unstructured":"Herman, D. et al. Histone deacetylase inhibitors reverse gene silencing in Friedreich\u2019s ataxia. Nat. Chem. Biol. 2, 551\u2013558 (2006).","journal-title":"Nat. Chem. Biol."},{"key":"138_CR29","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1128\/MCB.01516-07","volume":"28","author":"LP Wu","year":"2008","unstructured":"Wu, L. P. et al. Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Mol. Cell Biol. 28, 3219\u20133235 (2008).","journal-title":"Mol. Cell Biol."},{"key":"138_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4161\/epi.1.1.2375","volume":"1","author":"C Mund","year":"2006","unstructured":"Mund, C., Brueckner, B. & Lyko, F. Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications. Epigenetics 1, 7\u201313 (2006).","journal-title":"Epigenetics"},{"key":"138_CR31","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/leu.2008.397","volume":"23","author":"C Flotho","year":"2009","unstructured":"Flotho, C. et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23, 1019\u20131028 (2009).","journal-title":"Leukemia"},{"key":"138_CR32","first-page":"2989","volume":"33","author":"A Gnyszka","year":"2013","unstructured":"Gnyszka, A., Jastrzebski, Z. & Flis, S. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res. 33, 2989\u20132996 (2013).","journal-title":"Anticancer Res."},{"key":"138_CR33","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.blre.2011.06.002","volume":"25","author":"A Tefferi","year":"2011","unstructured":"Tefferi, A. & Pardanani, A. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective. Blood. Rev. 25, 229\u2013237 (2011).","journal-title":"Blood. Rev."},{"key":"138_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/2040620712461047","volume":"4","author":"MB Sonbol","year":"2013","unstructured":"Sonbol, M. B. et al. Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther. Adv. Hematol. 4, 15\u201335 (2013).","journal-title":"Ther. Adv. Hematol."},{"key":"138_CR35","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1182\/blood-2011-10-388538","volume":"119","author":"M Gupta","year":"2012","unstructured":"Gupta, M. et al. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. Blood 119, 2844\u20132853 (2012).","journal-title":"Blood"},{"key":"138_CR36","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/ajh.23658","volume":"89","author":"TE Witzig","year":"2014","unstructured":"Witzig, T. E. et al. Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma. Am. J. Hematol. 89, 417\u2013422 (2014).","journal-title":"Am. J. Hematol."},{"key":"138_CR37","doi-asserted-by":"publisher","first-page":"16686","DOI":"10.1074\/jbc.M116.736868","volume":"291","author":"D Beck","year":"2016","unstructured":"Beck, D. et al. Synthetic lethal screen demonstrates that a JAK2 inhibitor suppresses a BCL6-dependent IL10RA\/JAK2\/STAT3 pathway in high grade B-cell lymphoma. J. Biol. Chem. 291, 16686\u201316698 (2016).","journal-title":"J. Biol. Chem."},{"key":"138_CR38","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.ajpath.2017.01.004","volume":"187","author":"SH Sim","year":"2017","unstructured":"Sim, S. H. et al. Novel JAK3-activating mutations in extranodal NK\/T-cell lymphoma, nasal type. Am. J. Pathol. 187, 980\u2013986 (2017).","journal-title":"Am. J. Pathol."},{"key":"138_CR39","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1517\/13543776.2012.729579","volume":"22","author":"J Fahy","year":"2012","unstructured":"Fahy, J., Jeltsch, A. & Arimondo, P. B. DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies. Expert Opin. Ther. Pat. 22, 1427\u20131442 (2012).","journal-title":"Expert Opin. Ther. Pat."},{"key":"138_CR40","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1080\/10428194.2016.1247956","volume":"58","author":"AJ Moskowitz","year":"2017","unstructured":"Moskowitz, A. J. & Horwitz, S. M. Targeting histone deacetylases in T-cell lymphoma. Leuk. Lymphoma 58, 1306\u20131319 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"138_CR41","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","volume":"2","author":"J Dupuis","year":"2015","unstructured":"Dupuis, J. et al. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study. Lancet Haematol. 2, e160\u2013e165 (2015).","journal-title":"Lancet Haematol."},{"key":"138_CR42","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/bjh.12326","volume":"162","author":"Y Oki","year":"2013","unstructured":"Oki, Y. et al. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br. J. Haematol. 162, 138\u2013141 (2013).","journal-title":"Br. J. Haematol."},{"key":"138_CR43","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s00277-014-2009-0","volume":"93","author":"G Hopfinger","year":"2014","unstructured":"Hopfinger, G. et al. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed\/refractory peripheral T cell lymphoma (PTCL): report of a phase I\/II trial. Ann. Hematol. 93, 459\u2013462 (2014).","journal-title":"Ann. Hematol."},{"key":"138_CR44","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","volume":"25","author":"PL Zinzani","year":"2007","unstructured":"Zinzani, P. L. et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25, 4293\u20134297 (2007).","journal-title":"J. Clin. Oncol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0138-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0138-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0138-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T11:39:16Z","timestamp":1671536356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0138-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":44,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11]]}},"alternative-id":["138"],"URL":"https:\/\/doi.org\/10.1038\/s41408-018-0138-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,12]]},"assertion":[{"value":"11 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"110"}}